Fairvalue-Calculator Fairvalue-Calculator
EN DE

Finch Therapeutics Group (FNCH) Fair Value & Analysis

Healthcare · US · Market cap $14.8M

Price$7.45
Fair Value$3.79
Upside-49.1%
Quality92/100
Evidence: Low Range $2.83 – $5.65

Fair value as of: Jun 25, 2026

✦ Find undervalued quality stocks — 34,000+ analysed Find stocks →

Analysis

Finch Therapeutics Group (FNCH) currently trades at $7.45, while our model-based Fair Value estimate is $3.79 — implying the stock looks roughly 49.1% overvalued today. We read business quality at 92/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: low).

About the company

Finch Therapeutics Group, Inc., a clinical-stage microbiome therapeutics company, develops a novel class of orally administered biological drugs in the United States. The company develops FIN-211, a microbiome candidate designed to address the gastrointestinal and behavioral symptoms of autism spectrum disorder; and FIN-524 for the prevention, diagnosis, theragnosis or treatment of diseases in humans, including ulcerative colitis; FIN-525 for the treatment of Crohn's disease; and other microbiome product candidates. The company has collaboration and license agreements with Takeda Pharmaceutical Company Limited; and license agreements with Skysong Innovations LLC, OpenBiome, Arizona State University, and University of Minnesota. Finch Therapeutics Group, Inc. was incorporated in 2014 and is based in Boston, Massachusetts. On March 22, 2026, Finch Therapeutics Group, Inc., along with its affiliates, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy …

Open the full interactive analysis →

Similar stocks

Vertex Pharmaceuticals Incorporated (VRTX34) -32% Regeneron Pharmaceuticals, Inc (REGN) -4% UCB SA (UCB) -23% argenx SE (ARGNF) -57% Samsung Biologics Co (207940) +1% Alnylam Pharmaceuticals, Inc (ALNY) -82%

Frequently asked questions

Is Finch Therapeutics Group (FNCH) undervalued?
As of Jun 25, 2026, our model estimates a fair value of $3.79 versus a price of $7.45 — about −49% (overvalued). Model-based estimate, not financial advice.
What is the fair value of FNCH?
Our 21-model fair value for Finch Therapeutics Group is $3.79 (as of Jun 25, 2026), built from audited fundamentals. The current price is $7.45.
What is the quality score of FNCH?
Finch Therapeutics Group has a Quality Score of 92/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.